Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01662102 · ClinicalTrials.gov registry record · Phase 3
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
A Phase 3 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT01662102 is a Phase 3 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT01662102, a Phase 3 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of consolidation treatment Zevalin® versus maintenance treatment with Rituxan® on progression-free survival (PFS) following response induction with chemotherapy plus rituximab in previously untreated participants with follicular lymphoma.
Interventions
- DRUG Rituximab
- DRUG Zevalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-12-11 |
| Est. Completion | 2013-03-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01662102
The ClinicalTrials.gov registry entry for NCT01662102 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT01662102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01662102 about?
NCT01662102 is a clinical study titled "Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)". The purpose of this study is to evaluate the effect of consolidation treatment Zevalin® versus maintenance treatment with Rituxan® on progression-free survival (PFS) following response induction with chemotherapy plus rituximab in previously untreated participants with follicular lymphoma.
What is the current status of trial NCT01662102?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2012-12-11. Estimated completion is 2013-03-05.
What interventions are being tested in trial NCT01662102?
The interventions under investigation include: Rituximab (DRUG), Zevalin (DRUG).
Who is sponsoring clinical trial NCT01662102?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.